Those who were eligible, had an aortic valve annulus area of ≤430mm as per the computed tomography measurements, and “suitable” anatomy for transfemoral TAVR with either an Evolut PRO/PRO+/FX or a ...

2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...

2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 Ultra™ ...

The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes.

In addition, all patients undergo transthoracic echocardiographic assessment of aortic valve anatomy, transvalvular ... such as when annular or leaflet calcification is minimal, making ...

In patients with aortic stenosis and a small aortic annulus, results showed comparable composite outcome of mortality, disabling stroke, and heart failure hospitalization, and continued superior ...